Arcus Biosciences (RCUS) Competitors $8.17 +0.22 (+2.77%) As of 06/30/2025 03:58 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RCUS vs. SWTX, RNA, RARE, ACLX, PTGX, AAPG, SRRK, MTSR, KYMR, and VKTXShould you be buying Arcus Biosciences stock or one of its competitors? The main competitors of Arcus Biosciences include SpringWorks Therapeutics (SWTX), Avidity Biosciences (RNA), Ultragenyx Pharmaceutical (RARE), Arcellx (ACLX), Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), Scholar Rock (SRRK), Metsera (MTSR), Kymera Therapeutics (KYMR), and Viking Therapeutics (VKTX). These companies are all part of the "pharmaceutical products" industry. Arcus Biosciences vs. Its Competitors SpringWorks Therapeutics Avidity Biosciences Ultragenyx Pharmaceutical Arcellx Protagonist Therapeutics Ascentage Pharma Group International Scholar Rock Metsera Kymera Therapeutics Viking Therapeutics Arcus Biosciences (NYSE:RCUS) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations. Which has more volatility & risk, RCUS or SWTX? Arcus Biosciences has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Do analysts recommend RCUS or SWTX? Arcus Biosciences presently has a consensus price target of $21.29, indicating a potential upside of 160.54%. SpringWorks Therapeutics has a consensus price target of $52.57, indicating a potential upside of 11.88%. Given Arcus Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Arcus Biosciences is more favorable than SpringWorks Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcus Biosciences 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.89SpringWorks Therapeutics 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13 Do institutionals and insiders believe in RCUS or SWTX? 92.9% of Arcus Biosciences shares are owned by institutional investors. 9.6% of Arcus Biosciences shares are owned by company insiders. Comparatively, 7.8% of SpringWorks Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has higher earnings and valuation, RCUS or SWTX? SpringWorks Therapeutics has lower revenue, but higher earnings than Arcus Biosciences. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcus Biosciences$258M3.35-$283M-$4.19-1.95SpringWorks Therapeutics$191.59M18.48-$258.13M-$3.41-13.78 Does the media refer more to RCUS or SWTX? In the previous week, Arcus Biosciences had 5 more articles in the media than SpringWorks Therapeutics. MarketBeat recorded 10 mentions for Arcus Biosciences and 5 mentions for SpringWorks Therapeutics. SpringWorks Therapeutics' average media sentiment score of 1.00 beat Arcus Biosciences' score of 0.24 indicating that SpringWorks Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 0 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral SpringWorks Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is RCUS or SWTX more profitable? SpringWorks Therapeutics has a net margin of -115.60% compared to Arcus Biosciences' net margin of -258.94%. SpringWorks Therapeutics' return on equity of -51.10% beat Arcus Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Arcus Biosciences-258.94% -70.58% -32.97% SpringWorks Therapeutics -115.60%-51.10%-43.80% SummaryArcus Biosciences beats SpringWorks Therapeutics on 11 of the 17 factors compared between the two stocks. Get Arcus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RCUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RCUS vs. The Competition Export to ExcelMetricArcus BiosciencesMED IndustryMedical SectorNYSE ExchangeMarket Cap$841.79M$2.84B$5.46B$20.29BDividend YieldN/A2.70%5.36%3.76%P/E Ratio-1.9521.1526.4427.49Price / Sales3.35259.51405.3238.28Price / CashN/A41.2925.8817.85Price / Book1.547.247.944.54Net Income-$283M-$55.05M$3.15B$985.09M7 Day Performance-6.79%-1.01%0.63%0.88%1 Month Performance-9.02%5.98%4.96%4.04%1 Year Performance-46.58%0.83%32.55%13.29% Arcus Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RCUSArcus Biosciences3.0056 of 5 stars$8.17+2.8%$21.29+160.5%-46.4%$841.79M$258M-1.95500SWTXSpringWorks Therapeutics1.537 of 5 stars$46.97+0.0%$52.57+11.9%+24.7%$3.54B$191.59M-13.77230RNAAvidity Biosciences2.3492 of 5 stars$29.15-0.5%$66.56+128.3%-30.5%$3.53B$10.90M-9.72190RAREUltragenyx Pharmaceutical3.9129 of 5 stars$36.83-0.8%$87.00+136.2%-11.5%$3.51B$560.23M-6.261,294ACLXArcellx2.8628 of 5 stars$63.62+1.0%$111.23+74.8%+19.3%$3.47B$107.94M-21.2880Positive NewsPTGXProtagonist Therapeutics1.0441 of 5 stars$53.36+0.0%$66.10+23.9%+59.5%$3.31B$434.43M71.15120AAPGAscentage Pharma Group InternationalN/A$37.15-0.6%N/AN/A$3.26B$134.35M0.00600Positive NewsSRRKScholar Rock3.6519 of 5 stars$33.28-2.2%$42.67+28.2%+325.2%$3.23B$33.19M-13.15140MTSRMetseraN/A$29.00-2.0%$55.00+89.7%N/A$3.11BN/A0.0081Gap DownKYMRKymera Therapeutics3.0674 of 5 stars$46.29+0.9%$59.82+29.2%+46.2%$2.99B$47.07M-14.93170Trending NewsInsider TradeAnalyst RevisionVKTXViking Therapeutics4.12 of 5 stars$24.86-4.4%$87.15+250.6%-50.0%$2.92BN/A-21.6220Gap Up Related Companies and Tools Related Companies SpringWorks Therapeutics Competitors Avidity Biosciences Competitors Ultragenyx Pharmaceutical Competitors Arcellx Competitors Protagonist Therapeutics Competitors Ascentage Pharma Group International Competitors Scholar Rock Competitors Metsera Competitors Kymera Therapeutics Competitors Viking Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:RCUS) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RCUS Stock Alerts